Intra-Cellular TherapiesITCI
13F holders, Q2 2025 (June 30)3holders −392
0new positions
390sold out
$78.58avg. 13F price*
At the end of Q2 2025, 3 institutions reported holding Intra-Cellular Therapies Inc. (ITCI) in their 13F filings, down 392 from Q1 2025. 0 opened new positions and 390 sold out. The largest holders were DekaBank Deutsche Girozentrale ($4.1M), Osaic Holdings, Inc. ($60K) and Huntington National Bank ($3K).
- Company
- Intra-Cellular Therapies Inc.
- CUSIP
- 46116X101
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 390 | $13.5B |
All 13F filers, Q1 2025 → Q2 2025: 102,440,978 shares sold, net −102,440,978 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| DekaBank Deutsche Girozentrale | 0.01% | No change | 51,997 | $4.1M |
| Osaic Holdings, Inc. | 0.00% | Reduce -21.7% | 797 | $60K |
| Huntington National Bank | 0.00% | Reduce -99.6% | 1 | $3K |
"% of holder's portfolio" is ITCI's weight in each manager's 13F, not the share of Intra-Cellular Therapies Inc. the manager owns.